PC
CORT icon

Prairiewood Capital’s Corcept Therapeutics CORT Stock Holding History

Prairiewood Capital’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-26,143
Closed -$684K – 67
2020
Q4 		$684K Buy
+26,143
New +$551K 0.7% 45

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Prairiewood Capital's CORT Position: Q1 2021 in Review

Prairiewood Capital sold out of Corcept Therapeutics (CORT) in Q1 2021, closing a stake of 26,143 shares — an estimated $684K sold.

Prairiewood Capital first reported a position in CORT in Q4 2020 and held it in 1 quarter. The position peaked at $684K in Q4 2020. 209 funds tracked by Wall St. Rank hold CORT as of Q1 2021.

  • Prairiewood Capital reported no remaining Corcept Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Prairiewood Capital sold 26,143 Corcept Therapeutics shares in Q1 2021, an estimated $684K.
  • Prairiewood Capital first reported a position in Corcept Therapeutics in Q4 2020 and held it in 1 quarter.
  • Prairiewood Capital's Corcept Therapeutics position peaked at $684K in Q4 2020.
  • 209 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2021.

Based on Prairiewood Capital's 13F filing for Q1 2021, filed 13 Apr 2021.